AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer—2026 Update

2026/07/17 by Andreas Hartkopf, Ute-Susann Albert, Rupert Bartsch +44

paper · doi:10.1016/j.breast.2026.104873

published in The Breast 89, 104873 (Elsevier BV)

crossref created 2026/07/17 · crossref deposited 2026/08/08 · crossref indexed 2026/08/08 · crossref issued 2026/10/01 · crossref published 2026/10/01 · crossref published-print 2026/10/01

Citations

• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update
• Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer
• Pembrolizumab for Early Triple-Negative Breast Cancer
• Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
• Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
• Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer